Pharmacokinetic determinants of carbapenem therapy in neonates and children

Pediatric Infectious Disease Journal

Volumn 15, Issue 8, 1996, Pages 733-737

  Blumer, Jeffrey L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

antimicrobial activity; Carbapenems; children; imipenem; meropenem; newborn; pharmacokinetics

Indexed keywords

CARBAPENEM; CILASTATIN; IMIPENEM; MEROPENEM;

ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; CHILD; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; NEWBORN; PRIORITY JOURNAL;

AREA UNDER CURVE; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; IMIPENEM; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 0029782773     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199608000-00034     Document Type: Conference Paper

References (24)

1. Blumer JL. Carbapenems in pediatrics. Scand J Infect Dis 1995;Suppl 96:38-44.
2. Brogden RN, Heel RC. Aztreonam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1986;31:96-130.
3. Oates JA, Wood AJJ. Fluoroquinolone antimicrobial agents. N Engl J Med 1991;324:384-94.
4. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy commission. Pediatr Infect Dis J 1995;14:1-9.
5. Buckley MM, Brogden RN, Barradell LB, Goa KL. Imipenem/ cilastatin: a reappraisal of its antibacterial activity, pharmacokinetics, and therapeutic efficacy. Drugs 1992;44:408-44.
6. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50:73-101.
7. Kropp H, Sundelof JG, Hajdu R, et al. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-1. Antimicrob Agents Chemother 1982;22:62-70.
8. Birnbaum J, Kahan FM, Kropp H, MacDonald, JS. Carbapenems, a new class of beta-lactam antibiotics: discovery and development of imipenem/cilastatin. Am J Med 1985; 78(Suppl 6A):3-21.
9. Fukasawa M, Sumita Y, Harabe ET, Tanio T, Nouda H, Kohzuki T. Stability of meropenem and the effect of 1-beta-methyl substitution on its stability in the presence of renal dehydropeptidase-I. Antimicrob Agents Chemother 1992;36: 1577-9.
10. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995;Suppl 96:11-16.
11. Norrby SR, Bjornegard B, Ferber F, Jones KH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983;12(Suppl D):109-24.
12. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24(Suppl A):311-20.
13. Reed MD, Kliegman RM, Yamashita TS, Myers CM, Blumer JL. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother 1990;34:1172-7.
14. Gruber WC, Rench MA, Garcia-Prats JA, Edwards MS, Baker CJ. Single-dose pharmacokinetics of imipenemcilastatin in neonates. Antimicrob Agents Chemother 1985; 27:511-14.
15. Jacobs RF, Kearns GL, Trang JM, et al. Single-dose pharmacokinetics of imipenem in children. Pediatr 1984;105:996-1001.
16. Martinkova J, de Groot R, Chladek J, et al. Meropenem pharmacokinetics in pre-term and full-term neonates [Abstract 686]. In: Program and Abstracts of the 7th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, March 26 to 30, 1995:133.
17. Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother 1995;39:1721-5.
18. Besunder JB, Reed MD, Blumer JL. Drug disposition in the neonate: a critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part 1). Clin Pharmacokinet 1988;14:189-216.
19. Edwards JR, Turner PJ. Laboratory data which differentiate meropenem and imipenem. Scand J Infect Dis 1995;Suppl 96:5-10.
20. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(Suppl A):1-17.
21. Sunagawa M, Matsumura H, Inoue T, Fukasawa M, Kato M. A novel carbapenem antibiotic, SM-7338: structure activity relationships. J Antibiot 1990;43:519-32.
22. Drusano GL, Ryan PA, Standiford HC, Moody MR, Schimpff SC. Integration of selected pharmacokinetic and microbiological properties of three beta-lactam antibiotics: a hypothesis for rational comparison. Rev Infect Dis 1984;6:357-63.
23. Walker R, Andes D, Cinklin R, Ebert S, Craig W. Pharmacodynamic activities of meropenem in an animal infection model [Abstract A91]. In: Proceedings and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4 to 7, 1994. Washington, DC: American Society for Microbiology, 1994:147.
24. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.